BIIBBiogen
$225.73+57% 1Y
$225.73
$135.6752 weeks$228.71
BIIB in its own filings
BIIB's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
534
Events found in the filings · across 2,717 filings · the record starts in 1996
- Hard flags
- 1
Hard flags
- Most recent filing
- Jul 29, 2026
Most recent filing · Form 10-Q
- Record starts
- May 21, 1996
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Oct 29, 2026
- Late periodic report2 occurrences
- 2006-08-10
- SEC comment-letter activity51 occurrences
- 2022-05-24
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 29, 2026Cambridge, Mass. – July 29, 2026.Earnings release · press release
- May 14, 2026CVR Agreement As previously disclosed, on March 31, 2026, Biogen Inc., a Delaware corporation (“Biogen”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Apellis Pharmaceuticals, Inc., a Delaware corporation (“Apellis”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a wholly …Material agreement entered · Form 8-K
- Mar 31, 2026Agreement and Plan of Merger On March 31, 2026, Biogen Inc., a Delaware corporation (“Biogen”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Apellis Pharmaceuticals, Inc., a Delaware corporation (“Apellis”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a wholly owned …Material agreement entered · Form 8-K
- Mar 11, 2026On March 11, 2026, Biogen Inc. (the “Company”) announced that Susan H. Alexander, Chief Legal Officer, will depart from the Company effective as of the end May, 2026.Director or officer change · Form 8-K
- Feb 11, 2026On February 11, 2026, Caroline Dorsa, Chair of the Biogen Inc. (“Biogen” or the “Company”) Board of Directors (the “Board”) announced that she would not stand for re-election to the Board at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”)Director or officer change · Form 8-K
- Feb 6, 2026Cambridge, Mass. – February 6, 2026.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Cheap stocks by free cash flow yield
Drug Manufacturers, General
The closest names by size in the same industry